# EDGAR Filing Document

**Accession Number:** 0001255856
**File Stem:** 0000899243-23-002183
**Filing Date:** 2023-1
**Character Count:** 8977
**Document Hash:** 20325e787c86dfdb9097a4654c0d5369
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-002183.hdr.sgml**: 20230119

**ACCESSION NUMBER**: 0000899243-23-002183

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230119

**FILED AS OF DATE**: 20230119

**DATE AS OF CHANGE**: 20230119

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** BAILEY MICHAEL P
- **CENTRAL INDEX KEY:** 0001255856

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34655
- **FILM NUMBER:** 23538150

**BUSINESS ADDRESS:**
- **STREET 1:** IMCLONE SYSTEMS INCORPORATED
- **STREET 2:** 180 VARICK STREET, 6TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10014
- **BUSINESS PHONE:** 6466385078

**MAIL ADDRESS:**
- **STREET 1:** IMCLONE SYSTEMS INCORPORATED
- **STREET 2:** 180 VARICK STREET, 6TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10014
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVEO PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001325879
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 043581650
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 30 WINTER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02108
- **BUSINESS PHONE:** 857-400-0101

**MAIL ADDRESS:**
- **STREET 1:** 30 WINTER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AVEO PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20050503

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>BAILEY MICHAEL P<br><sub>(Last) (First) (Middle)</sub><br>C/O AVEO PHARMACEUTICALS, INC.<br>30 WINTER STREET<br><sub>(Street)</sub><br>BOSTON, MA 02108<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-19 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President & CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>AVEO PHARMACEUTICALS, INC. [ AVEO ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-01-19 |  | D |  | 333167 | D | 15.00<sup>(1)</sup> | 0 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $77.20 | 2023-01-19 |  | D |  |  | 3249 | <sup>(2)</sup> | 2023-01-24 | Common Stock | 3249 | <sup>(2)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $25.10 | 2023-01-19 |  | D |  |  | 11999 | <sup>(2)</sup> | 2023-06-26 | Common Stock | 11999 | <sup>(2)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $17.70 | 2023-01-19 |  | D |  |  | 7499 | <sup>(2)</sup> | 2024-01-29 | Common Stock | 7499 | <sup>(2)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $8.40 | 2023-01-19 |  | D |  |  | 90000 | <sup>(2)</sup> | 2025-01-06 | Common Stock | 90000 | <sup>(2)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $10.80 | 2023-01-19 |  | D |  |  | 46000 | <sup>(2)</sup> | 2026-01-07 | Common Stock | 46000 | <sup>(2)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $6.00 | 2023-01-19 |  | D |  |  | 75366 | <sup>(2)</sup> | 2027-02-07 | Common Stock | 75366 | <sup>(2)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $30.80 | 2023-01-19 |  | D |  |  | 99999 | <sup>(2)</sup> | 2028-02-01 | Common Stock | 99999 | <sup>(2)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $15.70 | 2023-01-19 |  | D |  |  | 16750 | <sup>(2)</sup> | 2024-06-19 | Common Stock | 16750 | <sup>(2)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $6.20 | 2023-01-19 |  | D |  |  | 93500 | <sup>(2)</sup> | 2029-02-06 | Common Stock | 93500 | <sup>(2)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $5.60 | 2023-01-19 |  | D |  |  | 35302 | <sup>(2)</sup> | 2030-02-05 | Common Stock | 35302 | <sup>(2)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $9.12 | 2023-01-19 |  | D |  |  | 275100 | <sup>(2)</sup> | 2031-02-05 | Common Stock | 275100 | <sup>(2)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $3.67 | 2023-01-19 |  | D |  |  | 625192 | <sup>(2)</sup> | 2032-02-15 | Common Stock | 625192 | <sup>(2)</sup> | 0 | D |  |

---

### Footnotes:

(1) Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.

(2) This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.

**Remarks:**
On January 19, 2022, pursuant to the Agreement and Plan of Merger (as it may be amended from time to time, referred to as the "Merger Agreement"), by and among LG Chem, Ltd. ("Parent"), Acacia acquisition Sub, Inc. ("Merger Sub") and AVEO Pharmaceuticals, Inc. (the "Company"), dated as of October 18, 2022, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of the Company's common stock automatically converted into the right to receive $15.00 per share in cash (the "Merger Consideration").

**Signature:** /s/ Danielle V. Holland, attorney in fact  
**Date:** 2023-01-19

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**